The price of Altimmune Inc (NASDAQ:ALT) shares last traded on Wall Street fell -53.18% to $3.61.
ALT stock price is now -36.63% away from the 50-day moving average and -44.94% away from the 200-day moving average. The market capitalization of the company currently stands at $292.79M.
On January 08, 2025, Stifel recently initiated its ‘Buy’ rating on the stock quoting a target price of $18, while ‘UBS’ rates the stock as ‘Buy’
In other news, Sohn Catherine A., Director bought 1,000 shares of the company’s stock on Mar 17 ’25. The stock was bought for $5,784 at an average price of $5.78. Upon completion of the transaction, the Director now directly owns 1,000 shares in the company, valued at $3610.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 13 ’25, Chief Financial Officer WEAVER GREGORY L bought 10,000 shares of the business’s stock. A total of $51,996 was incurred on buying the stock at an average price of $5.20. This leaves the insider owning 10,000 shares of the company worth $36100.0. A total of 1.04% of the company’s stock is owned by insiders.
During the past 12 months, Altimmune Inc has had a low of $3.55 and a high of $11.16. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 15.82, and a quick ratio of 15.82. The fifty day moving average price for ALT is $5.6968 and a two-hundred day moving average price translates $6.556575 for the stock.
The latest earnings results from Altimmune Inc (NASDAQ: ALT) was released for 2025-03-31. The net profit margin was -451200.00% and return on equity was -57.28% for ALT. The company reported revenue of $5000.0 for the quarter, compared to $5000.0 a year earlier.
